Joseph Sgouros1, Gerasimos Aravantinos2, George Kouvatseas3, Anna Rapti4, George Stamoulis4, Anastasios Bisvikis4, Helen Res4, Epameinondas Samantas4. 1. 3rd Medical Oncology Department, "Agii Anargiri" General Cancer Hospital, Kaliftaki, N. Kifissia, 14564, Greece. josephsgouros@yahoo.co.uk. 2. 2nd Medical Oncology Department, "Agii Anargiri" General Cancer Hospital, Kaliftaki, N. Kifissia, 14564, Greece. 3. Health Data Specialists, Ltd, 22 Katehaki Str, Athens, 11525, Greece. 4. 3rd Medical Oncology Department, "Agii Anargiri" General Cancer Hospital, Kaliftaki, N. Kifissia, 14564, Greece.
Abstract
PURPOSE: Most stage II or III colorectal cancer patients are receiving nowadays a 4 to 6-month course of adjuvant chemotherapy. However, delays between cycles, reductions in the doses of chemotherapy drugs, or even permanent omissions of chemotherapy cycles might take place due to side effects or patient's preference. We examined the impact of these treatment modifications on recurrence-free survival (RFS) and overall survival (OS). METHODS: We retrospectively collected data from colorectal cancer patients who had received adjuvant chemotherapy in our Department. Patients were categorized in five groups based on whether they had or not delays between chemotherapy cycles, dose reductions, and permanent omissions of chemotherapy cycles. Three-year RFS and OS of the five different groups were compared using the log-rank test and the Sidak approach. RESULTS: Five hundred and eight patients received treatment. Twenty seven percent of the patients had the full course of chemotherapy; the others had delays, dose reductions, or early termination of the treatment. No statistically significant differences were observed in 3-year RFS and OS between the five groups. A trend for worse RFS was noticed with early termination of treatment. A similar trend was also noticed for OS but only for stage II patients. CONCLUSION: In colorectal cancer patients, receiving adjuvant chemotherapy, delays between chemotherapy cycles, dose reductions of chemotherapy drugs, or even early termination of the treatment course do not seem to have a negative impact in 3-year RFS and OS; however, due to the trend of worse RFS in patients receiving shorter courses of chemotherapy, further studies are needed.
PURPOSE: Most stage II or III colorectal cancerpatients are receiving nowadays a 4 to 6-month course of adjuvant chemotherapy. However, delays between cycles, reductions in the doses of chemotherapy drugs, or even permanent omissions of chemotherapy cycles might take place due to side effects or patient's preference. We examined the impact of these treatment modifications on recurrence-free survival (RFS) and overall survival (OS). METHODS: We retrospectively collected data from colorectal cancerpatients who had received adjuvant chemotherapy in our Department. Patients were categorized in five groups based on whether they had or not delays between chemotherapy cycles, dose reductions, and permanent omissions of chemotherapy cycles. Three-year RFS and OS of the five different groups were compared using the log-rank test and the Sidak approach. RESULTS: Five hundred and eight patients received treatment. Twenty seven percent of the patients had the full course of chemotherapy; the others had delays, dose reductions, or early termination of the treatment. No statistically significant differences were observed in 3-year RFS and OS between the five groups. A trend for worse RFS was noticed with early termination of treatment. A similar trend was also noticed for OS but only for stage II patients. CONCLUSION: In colorectal cancerpatients, receiving adjuvant chemotherapy, delays between chemotherapy cycles, dose reductions of chemotherapy drugs, or even early termination of the treatment course do not seem to have a negative impact in 3-year RFS and OS; however, due to the trend of worse RFS in patients receiving shorter courses of chemotherapy, further studies are needed.
Entities:
Keywords:
Adjuvant chemotherapy; Colorectal cancer; Delays between chemotherapy cycles; Dose reductions; Omission of chemotherapy cycles
Authors: Daniel G Haller; Josep Tabernero; Jean Maroun; Filippo de Braud; Timothy Price; Eric Van Cutsem; Mark Hill; Frank Gilberg; Karen Rittweger; Hans-Joachim Schmoll Journal: J Clin Oncol Date: 2011-03-07 Impact factor: 44.544
Authors: I Chau; A R Norman; D Cunningham; D Tait; P J Ross; T Iveson; M Hill; T Hickish; F Lofts; D Jodrell; A Webb; J R Oates Journal: Ann Oncol Date: 2005-02-02 Impact factor: 32.976
Authors: C G Moertel; T R Fleming; J S Macdonald; D G Haller; J A Laurie; P J Goodman; J S Ungerleider; W A Emerson; D C Tormey; J H Glick Journal: N Engl J Med Date: 1990-02-08 Impact factor: 91.245
Authors: R Glynne-Jones; N Counsell; P Quirke; N Mortensen; A Maraveyas; H M Meadows; J Ledermann; D Sebag-Montefiore Journal: Ann Oncol Date: 2014-04-08 Impact factor: 32.976
Authors: Thierry André; Timothy Iveson; Roberto Labianca; Jeffrey A Meyerhardt; Ioannis Souglakos; Takayuki Yoshino; James Paul; Alberto Sobrero; Julien Taieb; Anthony F Shields; Atsushi Ohtsu; Axel Grothey; Daniel J Sargent Journal: Curr Colorectal Cancer Rep Date: 2013
Authors: Devon J Boyne; Colleen A Cuthbert; Dylan E O'Sullivan; Tolulope T Sajobi; Robert J Hilsden; Christine M Friedenreich; Winson Y Cheung; Darren R Brenner Journal: JAMA Netw Open Date: 2019-05-03
Authors: Devon J Boyne; Dylan E O'Sullivan; Emily V Heer; Robert J Hilsden; Tolulope T Sajobi; Winson Y Cheung; Darren R Brenner; Christine M Friedenreich Journal: Cancer Med Date: 2020-01-21 Impact factor: 4.452